Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
AMAG is in the long-term down -85% below S&P in 7 years.
Description: AMAG Pharmaceuticals, Inc. develops and commercializes specialty pharmaceutical products. The company markets Feraheme (ferumoxytol) injection for use as an intravenous (IV) iron replacement therapy for the treatment of iron deficiency anemia in adult patients with chronic kidney disease; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. It markets Feraheme in the United States and Canada; and as Rienso in the European Union. The company sells Feraheme to authorized wholesalers and specialty distributors. AMAG Pharmaceuticals, Inc. has a license, development, and commercialization agreement with Takeda Pharmaceutical Company Limited to develop and commercialize Feraheme/Rienso as a therapeutic agent in Europe, certain Asia-Pacific countries, the Commonwealth of Independent States, Canada, India, and Turkey; and collaboration and exclusive license agreement with 3SBio for the development and commercialization of Feraheme as an IV iron rep
|Shares Outstanding||EPS||1.11||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||385.93%||Sales Growth - Q/Q||38.41%||P/E||14.77|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||11.63%||ROE||26.74%||ROI||15.98%|
|Current Ratio||1.71||Quick Ratio||1.61||Long Term Debt/Equity||1.51||Debt Ratio||0.45|
|Gross Margin||81.03%||Operating Margin||31.1%||Net Profit Margin||65.25%||Dividend Payout Ratio|
|Cash From Financing Activities||183.64 M||Cash From Investing Activities||-284.74 M||Cash From Operating Activities||71.69 M||Gross Profit||104.2 M|
|Net Profit||33.26 M||Operating Profit||61.12 M||Total Assets||1.64 B||Total Current Assets||555.48 M|
|Total Current Liabilities||323.97 M||Total Debt||483.2 M||Total Liabilities||926.3 M||Total Revenue||123.88 M|
|High 52 week||25.65||Low 52 week||10.34||Last close||10.34||Last change||-4.08%|
|RSI||40.26||Average true range||0.72||Beta||0.76||Volume||768.3 K|
|Simple moving average 20 days||-8.89%||Simple moving average 50 days||-14.38%||Simple moving average 200 days||-41.9%|
|Performance Week||-10.32%||Performance Month||-13.18%||Performance Quart||-38.12%||Performance Half||-56.92%|
|Performance Year||-21.96%||Performance Year-to-date||-31.93%||Volatility daily||4.01%||Volatility weekly||8.97%|
|Volatility monthly||18.39%||Volatility yearly||63.7%||Relative Volume||235.39%||Average Volume||747.72 K|
|New High||New Low|
2020-06-03 00:00:23 | Edited Transcript of AMAG earnings conference call or presentation 11-May-20 12:00pm GMT
2020-05-27 08:00:10 | AMAG Pharmaceuticals to Participate in Jefferies Virtual Global Healthcare Conference
2020-05-12 12:26:04 | AMAG Pharmaceuticals AMAG Reports Q1 Loss, Beats on Revenues
2020-05-11 12:00:37 | AMAG Pharmaceuticals Inc AMAG Q1 2020 Earnings Call Transcript
2020-05-11 09:45:01 | AMAG Pharmaceuticals AMAG Reports Q1 Loss, Tops Revenue Estimates
2020-05-11 07:32:04 | AMAG Pharmaceuticals: Q1 Earnings Insights
2020-05-06 06:51:00 | Should You Buy This Stock That Makes "Viagra for Women"?
2020-05-05 06:13:01 | Does The AMAG Pharmaceuticals, Inc. NASDAQ:AMAG Share Price Fall With The Market?
2020-04-28 12:33:04 | AMAG Pharmaceuticals AMAG Earnings Expected to Grow: What to Know Ahead of Q1 Release
2020-04-28 07:00:10 | AMAG Pharmaceuticals Appoints Scott Myers as President and Chief Executive Officer
2020-04-16 08:00:10 | AMAG Pharmaceuticals Provides COVID-19 Company Update
2020-04-03 11:30:03 | AMAG Pharmaceuticals AMAG Down 21.5% Since Last Earnings Report: Can It Rebound?
2020-04-02 13:23:05 | LLY, OXM, AMAG, MIST and CPIX as Zacks Bull and Bear of the Day
2020-04-01 10:15:02 | 3 Drugmakers Still Worth Betting on Amid Coronavirus Woes
2020-03-25 12:00:04 | AMAG Pharmaceuticals AMAG Moves to Buy: Rationale Behind the Upgrade
2020-03-12 22:33:38 | Edited Transcript of AMAG earnings conference call or presentation 4-Mar-20 1:00pm GMT
2020-03-09 09:49:01 | AMAG Sees High Feraheme Sales, To Sell Women Healthcare Drugs
2020-03-05 08:21:01 | AMAG Q4 Loss Wider Than Expected, Revenues Beat Estimates
2020-03-04 08:35:01 | AMAG Pharmaceuticals AMAG Reports Q4 Loss, Tops Revenue Estimates
2020-03-04 06:58:10 | AMAG Pharmaceuticals Announces Changes to Medical Development Organization
2020-03-01 08:31:17 | Have Insiders Been Buying AMAG Pharmaceuticals, Inc. NASDAQ:AMAG Shares?
2020-02-26 08:46:01 | Is a Surprise Coming for AMAG This Earnings Season?
2020-02-19 08:53:01 | Should You Buy AMAG Pharmaceuticals AMAG Ahead of Earnings?
2020-02-14 08:00:10 | AMAG Pharmaceuticals to Participate in Upcoming Investor Conferences
2020-01-14 12:00:05 | AMAG Pharmaceuticals AMAG Upgraded to Buy: Here's Why
2020-01-10 18:08:11 | AMAG to Sell Women Healthcare Drugs, CEO Resigns, Stock Down
2020-01-09 10:21:00 | Amag stock tumbles on CEO departure, divestiture plans
2020-01-09 09:55:44 | Waltham's Amag Pharma replacing CEO, cutting two products
2020-01-03 08:00:10 | AMAG Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference
2019-12-13 11:12:26 | Hedge Funds Are Souring On AMAG Pharmaceuticals, Inc. AMAG
2019-12-06 08:00:10 | 12 Biotech Stocks Primed For A Short Squeeze
2019-12-01 09:30:02 | Why Is AMAG Pharmaceuticals AMAG Up 9.7% Since Last Earnings Report?